12-132626314-G-C
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 0P and 0B.
The NM_006231.4(POLE):c.6334C>G(p.Leu2112Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000124 in 1,613,338 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L2112P) has been classified as Uncertain significance.
Frequency
Consequence
NM_006231.4 missense
Scores
Clinical Significance
Conservation
Publications
- POLE-related polyposis and colorectal cancer syndromeInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- colorectal cancer, susceptibility to, 12Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
- facial dysmorphism-immunodeficiency-livedo-short stature syndromeInheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Ambry Genetics
- intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and immunodeficiencyInheritance: AR Classification: STRONG Submitted by: G2P
- IMAGe syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Polymerase proofreading-related adenomatous polyposisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLE | NM_006231.4 | c.6334C>G | p.Leu2112Val | missense_variant | Exon 46 of 49 | ENST00000320574.10 | NP_006222.2 | |
POLE | XM_011534795.4 | c.6334C>G | p.Leu2112Val | missense_variant | Exon 46 of 48 | XP_011533097.1 | ||
POLE | XM_011534797.4 | c.5413C>G | p.Leu1805Val | missense_variant | Exon 38 of 40 | XP_011533099.1 | ||
POLE | XM_011534802.4 | c.3322C>G | p.Leu1108Val | missense_variant | Exon 22 of 24 | XP_011533104.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000328 AC: 5AN: 152230Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.00000803 AC: 2AN: 249092 AF XY: 0.00000741 show subpopulations
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1461108Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 726860 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152230Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74376 show subpopulations
ClinVar
Submissions by phenotype
not provided Uncertain:2
This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 2112 of the POLE protein (p.Leu2112Val). This variant is present in population databases (no rsID available, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with POLE-related conditions. ClinVar contains an entry for this variant (Variation ID: 240592). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on POLE protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.L2112V variant (also known as c.6334C>G), located in coding exon 46 of the POLE gene, results from a C to G substitution at nucleotide position 6334. The leucine at codon 2112 is replaced by valine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
Colorectal cancer, susceptibility to, 12;C3554576:Facial dysmorphism-immunodeficiency-livedo-short stature syndrome;C5193036:Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and immunodeficiency Uncertain:1
POLE NM_006231.3 exon 46 p.Leu2112Val (c.6334C>G): This variant has not been reported in the literature but is present in 0.02% (5/24720) of African alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/12-133202900-G-C?dataset=gnomad_r2_1). This variant is present in ClinVar (Variation ID:240592). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at